MindBio Therapeutics fast-tracks microdosing studies

Blackhawk’s MindBio Therapeutics Invests NZ$2.3 Million to Fast Track Psychedelic Microdosing Phase 2 Clinical Trials

MindBio Therapeutics invested NZ$2.3M to fast-track its research on microdosing LSD for depression and  end-of-life distress in late-stage cancer patients.

Blackhawk Growth Corp

PDF of article